Compare Natera, Inc. with Similar Stocks
Dashboard
1
The company has declared Positive results for the last 8 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 194.3 MM
- NET PROFIT(HY) Higher at USD -188.48 MM
- DEBTORS TURNOVER RATIO(HY) Highest at 7.14 times
2
Risky -
3
Reducing Promoter Confidence
4
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 28,017 Million (Mid Cap)
NA (Loss Making)
NA
0.00%
-0.76
-24.69%
22.37
Revenue and Profits:
Net Sales:
665 Million
(Quarterly Results - Dec 2025)
Net Profit:
47 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.02%
0%
-12.02%
6 Months
13.08%
0%
13.08%
1 Year
32.92%
0%
32.92%
2 Years
121.6%
0%
121.6%
3 Years
250.31%
0%
250.31%
4 Years
428.87%
0%
428.87%
5 Years
87.15%
0%
87.15%
Natera, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
42.37%
EBIT Growth (5y)
-57.80%
EBIT to Interest (avg)
-38.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
1.19
Tax Ratio
0.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
22.37
EV to EBIT
-76.93
EV to EBITDA
-86.02
EV to Capital Employed
89.02
EV to Sales
12.79
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-115.71%
ROE (Latest)
-24.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 125 Schemes (44.61%)
Foreign Institutions
Held by 356 Foreign Institutions (13.98%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
665.50
476.10
39.78%
Operating Profit (PBDIT) excl Other Income
-4.80
-56.90
91.56%
Interest
1.00
1.30
-23.08%
Exceptional Items
-3.90
0.00
Consolidate Net Profit
47.30
-53.80
187.92%
Operating Profit Margin (Excl OI)
-28.40%
-136.00%
10.76%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 39.78% vs 53.04% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 187.92% vs 31.03% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,306.10
1,696.90
35.90%
Operating Profit (PBDIT) excl Other Income
-262.50
-191.30
-37.22%
Interest
4.10
10.70
-61.68%
Exceptional Items
-3.90
0.00
Consolidate Net Profit
-208.20
-190.40
-9.35%
Operating Profit Margin (Excl OI)
-132.70%
-131.00%
-0.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 35.90% vs 56.74% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -9.35% vs 56.21% in Dec 2024
About Natera, Inc. 
Natera, Inc.
Pharmaceuticals & Biotechnology
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).
Company Coordinates 
Company Details
201 Industrial Rd Ste 410 , SAN CARLOS CA : 94070-2396
Registrar Details






